💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Protease (Pancrelipase)

CHEMBL1201482 Phase 4 Approuvé Enzyme
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Protease (pancrelipase) is a component of the pancreatic enzyme replacement product pancrelipase, derived from porcine pancreatic tissue, containing protease, lipase, and amylase activities that supplement deficient endogenous digestive enzyme secretion. It is used for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Mécanisme d'action

Provides exogenous replacement of the deficient or absent enzyme, enabling the metabolic processing of accumulated substrates and restoring normal metabolic function.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Provides exogenous replacement of the deficient or absent enzyme, enabling the metabolic processing of accumulated substrates and restoring normal metabolic function.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

Protease (pancrelipase) is a component of the pancreatic enzyme replacement product pancrelipase, derived from porcine pancreatic tissue, containing protease, lipase, and amylase activities that supplement deficient endogenous digestive enzyme secretion. It is used for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Provides exogenous replacement of the deficient or absent enzyme, enabling the metabolic processing of accumulated substrates and restoring normal metabolic function.

Yes, Protease (Pancrelipase) is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201482. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.